646483-08-1

Basic information

• Product Name: 4-hydroxy-5-Methyl-5-octylthiophen-2(5H)-one
• Synonyms: 4-hydroxy-5-Methyl-5-octylthiophen-2(5H)-one;PIRZFZMRZHTILE-UHFFFAOYSA-N
• CAS NO: 646483-08-1
• Molecular Formula: C₁₃H₂₂O₂S
• Molecular Weight: 242.37758
• Mol File: 646483-08-1.mol

Chemical Properties

• Boiling Point: 353.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.063±0.06 g/cm3(Predicted)
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 4-hydroxy-5-Methyl-5-octylthiophen-2(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxy-5-Methyl-5-octylthiophen-2(5H)-one(646483-08-1)
• EPA Substance Registry System: 4-hydroxy-5-Methyl-5-octylthiophen-2(5H)-one(646483-08-1)

Safety Data

• Hazardous Substances Data: 646483-08-1(Hazardous Substances Data)

Upstream product

• 1198410-66-0 (S,S)-2-tert-butyl-4-methyl-4-octyl-[1,3]oxathiolan-5-one 
• 1198410-71-7 C₁₃H₂₆O₂S 
• 111-87-5 octanol 
• 71091-89-9 n-octyl triflate 
• 1024810-14-7 2,2,4-trimethyl-4-octyl-[1,3]oxathiolan-5-one 
• 646483-06-9 (+/-)-2-acetylsulfanyl-2-methyldecanoic acid ethyl ester 
• 646483-04-7 2-mercapto-2-methyl-decanoic acid ethyl ester 

Downstream Products

• 646482-93-1 (+/-)-(5-methyl-5-octyl-2-oxo-5H-thiophen-4-yloxy)-acetic acid-N'-(4-chloro-phenyl)-hydrazide 
• 1198410-27-3 2-(2-methyl-2-octyl-5-oxo-2,5-dihydro-thiophen-3-yloxy)-N-phenylacetamide 
• 1198410-25-1 N-(4-chlorophenyl)-(5-methyl-5-octyl-2-oxo-thiophen-4-yloxy)-acetamide 

Relevant articles and documents

Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase

Fatty acid synthase (FAS) catalyzes the synthesis of palmitate from the sequential condensation of an acetyl primer with two carbon units added from malonyl-CoA. Inhibition of the β-ketoacyl synthase domain of mammalian FAS leads to selective cytotoxicity

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME

The class compounds of the present invention may be represented by Formula (I), wherein X may be O, S, or N. R1 and R2 are independently either H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME

Compounds having the following general formula, pharmaceutical compositions comprising the compounds, and methods of treating cancer, obesity, and microbial infections using such compositions: wherein: R1 = H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, aryl

NOVEL COMPUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME

A pharmaceutical composition comprising a phamaceurtical diluent and a compound of formula IV wherein R21= H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, -CH2OR25, -C(O)R25, -CO(O)R25, -C(O)NR25R26, -CH2C(O)R25, or -CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R22 = -OH, -OR27, -OCH2C(O)R27, -OCH2C(O)NHR27, -OC(O)R27, -OC(O)OR27, -OC(O)NHNH-R5, or -OC(O)NR27R28, where R27 and R28 are each independentlyH, C1 -C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R27 and R28 can each optionally contain halogen atoms; R23 and R24, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.